897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model
Alexis Weston(Translational Genomics Research Institute), Sunil Sharma, Monil Shah(South Texas Accelerated Research Therapeutics), Mohan R. Kaadige(University of Utah), Trason Thode(Translational Genomics Research Institute), Srinivas Rao Kasibhatla(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Jonathan Northrup(South Texas Accelerated Research Therapeutics), Brian Durbin(Translational Genomics Research Institute), Tithi Ghosh-Halder(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Katelyn Gutowsky(Translational Genomics Research Institute)
Cited by 2
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA Interaction
|Molecular and Cellular Biology|2014|41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24